 I. To assess 2-year overall survival in each treatment arm fluorouracil, irinotecan hydrochloride, and oxaliplatin modified mFOLFIRINOX and gemcitabine gemcitabine hydrochloridenab-paclitaxel paclitaxel albumin-stabilized nanoparticle formulation in patients with resectable pancreatic cancer. 